Loading
CRISPR and Genetic Engineering · Journal article
Georgetown Medical Review · August 21, 2026
Raises a question worth testing. It does not answer one.
This is a narrative review of CRISPR-Cas9 applications in animal models across four cardiovascular disease domains (congenital heart disease, hypertrophic cardiomyopathy, heart failure, and atherosclerosis). The review describes the methodological range and potential value of gene-edited animal models for identifying genetic drivers and supporting therapeutic development, but does not report quantitative synthesis, primary outcomes, or direct clinical evidence.
Narrative review article. Primary literature reporting CRISPR-Cas9 animal models in four cardiovascular disease domains. Intervention: CRISPR-Cas9 animal models for CVD research.
CRISPR-Cas9 animal models are used across 4 CVD domains to identify genetic drivers of disease Animal models support stages in genetic therapeutics development from gene target identification through therapeutic trials assessing risk-benefit Models parallel human genetic pathophysiology for specific disease processes
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This review contextualizes the role of CRISPR-Cas9 animal models in CVD research but does not provide evidence to guide clinical practice or therapeutic decisions. It is useful for understanding the translational pathway from basic gene editing research to potential human therapeutics.
This is a narrative review synthesizing applications of CRISPR-Cas systems in animal CVD models; it raises questions about translational potential rather than testing clinical hypotheses or reporting primary research findings.
As stated by the source record.
Quoted from the source exactly as published.
This review contextualizes the role of CRISPR-Cas9 animal models in CVD research but does not provide evidence to guide clinical practice or therapeutic decisions. It is useful for understanding the translational pathway from basic gene editing research to potential human therapeutics.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Cardiovascular disease (CVD) causes more deaths, more years of life lost, and more years lived with disability than any other major category of disease worldwide. Gene editing technologies, including the CRISPR-Cas9 system and its offshoots, are increasingly applied in CVD animal research models to identify genetic drivers of disease processes and to develop and test targeted therapeutics. To explore the potential impact and limitations of using animal models for these applications, this review examines studies in which the creation of a CRISPR-Cas9 animal model has been used to find genetic drivers and develop therapies. Studies were identified using OVID Medline, searching the past 10 years of the primary literature across 4 CVD domains: congenital heart disease, hypertrophic cardiomyopathy, heart failure, and atherosclerosis. The studies illustrate the vast range of gene editing applications and the value of models that parallel human genetic pathophysiology for specific disease processes. Besides furthering anatomical, clinical, and natural historical understanding of CVD pathologies and providing biological substrates in the development of screening and diagnostic tools, animal models support foundational stages in the development of genetic therapeutics, from gene target identification to discovery and development of gene-editing therapy mechanisms and delivery vehicles, through conducting therapeutic trials to assess the risk-benefit ratio.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.